Professor Jing Liu

Principle Investigator, High Magnetic Field Laboratory, Chinese Academy of Sciences

Room 417, Building 2, 350 Shushanhu Road, Hefei, 230031, P. R. China

Phone: +86-551-65593186

E-mail: jingliu@hmfl.ac.cn

We are interested in developing and application of novel chemical probes for molecular imaging and studying biological processes in cells and in animals. We are also working on design and developing small molecule drug-based diagnostic reagents for personalized targeted cancer therapy and translational medical research.

 

EDUCATION BACKGROUND

2001-2008: Ph.D./Chemistry, Texas A&M University, USA

1997-2001: B.S./Chemistry, Nankai University, China


RESEARCH EXPERIENCE

2013.2-now: Professor/Principal Investigator, High Magnetic Field Laboratory, Chinese Academy of Sciences, China

2009.8-2013.1: Research Fellow, Department of Cell Biology at Harvard Medical School, USA

2009.1-7: Postdoctoral Research Associate, Department of Chemistry at Texas A&M University, USA

PUBLICATIONS

  1. Aoli Wang#, Xixiang Li#, Hong Wu#, Fengming Zou#, Xiao-E Yan#, Cheng Chen, Chen Hu, Kailin Yu, Wenchao Wang, Peng Zhao, Jiaxin Wu, Ziping Qi, Wei Wang, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Cai-Hong Yun*, Jing Liu*, and Qingsong Liu*, Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutants Kinase Inhibitor with a Distinct Binding Mode, J. Med. Chem. 2017, DOI: 10.1021/acs.jmedchem.6b01907.
  2. Qianmao Liang#, Yongfei Chen#, Kailin Yu#, Cheng Chen#, Shouxiang Zhang#, Aoli Wang, Wei Wang, Hong Wu, Xiaochuan Liu, Beilei Wang, Li Wang, Zhenquan Hu, Wenchao Wang, Tao Ren, Shanchun Zhang, Qingsong Liu, Cai-Hong Yun*, Jing Liu*, Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl) amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor, Eur. J. Med. Chem. 2017, 131, 107-125.
  3. Chen Hu#, Aoli Wang#, Hong Wu#, Ziping Qi#, Xixiang Li#, Xiao-E Yan#, Cheng Chen, Kailin Yu, Fengming Zou, Wenchao Wang, Wei Wang, Jiaxin Wu, Juan Liu, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Cai-Hong Yun*, Jing Liu*, Qingsong Liu*, Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode”, Oncotarget 2017, in press.
  4. Hong Wu#, Qiong Huang#, Ziping Qi#, Yongfei Chen#, Aoli Wang, Cheng Chen, Qianmao Liang, Jinghua Wang, Wensheng Chen, Jin Dong, Kailin Yu, Chen Hu, Wenchao Wang, Xiaochuan Liu, Xiaoxiang Li, Nathanael S. Gray, Jing Liu*, Wei Wei*, Qingsong Liu*, Irreversible Inhibition of BTK Kinase by a Novel Highly Selective Inhibitor CHMFL-BTK-11 Suppresses Inflammatory Response in Rheumatoid Arthritis model, Scientific Reports 2017, DOI: 10.1038/s41598-017-00482-4.
  5. Juanjuan Liu#, Xingxing Yang#, Binhua Li, Junjun Wang, Wenchao Wang, Jing Liu, Qingsong Liu, Xin Zhang*, STK16 regulates actin dynamics to control Golgi organization and cell cycle, Scientific Reports 2017, 7: 44607.
  6. Xiaofei Liang,# Fengchao Lv,# Beilei Wang,# Kailin Yu,# Hong Wu, Ziping Qi, Zongru Jiang, Cheng Chen, Aoli Wang, Weili Miao, Wenchao Wang, Zhenquan Hu, Juan Liu, Xiaochuan Liu, Zheng Zhao, Li Wang, Shanchuan Zhang, Zi Ye, Chu Wang, Tao Ren, Yinsheng Wang, Qingsong Liu*, Jing Liu*, Discovery of 2‑((3-Acrylamido-4-methylphenyl)amino)‑N‑(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor, J. Med. Chem. 2017, 60(5):1793-1816.
  7. Qiang Wang#, Feiyang Liu#, Beilei Wang#, Fengming Zou#, Ziping Qi, Cheng Chen, Kailin Yu, Chen Hu, Shuang Qi, Wenchao Wang, Zhenquan Hu, Juan Liu, Wei Wang, Li Wang, Qianmao Liang, Shanchun Zhang, Tao Ren, Qingsong Liu*, Jing Liu*, Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent 4 Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding, J. Med. Chem. 2017, 60(1): 273-289.
  8. Aoli Wang#, Xiao-E Yan#, Hong Wu#, Wenchao Wang#, Chen Hu, Cheng Chen, Zheng Zhao, Peng Zhao, Xixiang Li, Li Wang, Beilei Wang, Zi Ye, Jinhua Wang, Chu Wang, Wei Zhang, Nathanael S. Gray, Ellen L. Weisberg, Liang Chen, Jing Liu*, Cai-Hong Yun*, Qingsong Liu*, Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation, Oncotarget 2016, 7(43): 69760-69769.
  9. Binhua Li#, Aoli Wang#, Juan Liu#, Ziping Qi#, Xiaochuan Liu#, Kailin Yu, Hong Wu, Cheng Chen, Chen Hu, Wenchao Wang, Jiaxin Wu, Zhenquan Hu, Ling Ye, Fengming Zou, Feiyang Liu, Beilei Wang, Li Wang, Tao Ren, Shaojuan Zhang, Mingfeng Bai, Shanchun Zhang, Jing Liu*, Qingsong Liu*, Discovery of N-((1-(4-(3-(3-((6,7-dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kinase, J. Med. Chem. 2016, 59(18): 8456-8472.
  10. Pengxiang Huang, Daniel Nedelcu, Miyako Watanabe, Cindy Jao, Youngchang Kim, Jing Liu, Adrian Salic, Cellular Cholesterol Directly Activates Smoothened in Hedgehog Signaling, Cell 2016, 166(5):1176-1187.e14.
  11. Xiaochuan Liu#, Aoli Wang#, Xiaofei Liang#, Juanjuan Liu#, Fengming Zou#, Cheng Chen#, Zheng Zhao, Yuanxin Deng, Hong Wu, Ziping Qi, Beilei Wan, Li Wang, Feiyang Liu, Yunhe Xu, Wenchao Wang, Stacey M. Fernandes, Richard M. Stone, Ilene A. Galinsky, Jennifer R. Brown, Teckpeng Loh, James. D. Griffin, Shanchun Zhang, Ellen L. Weisberg*, Xin Zhang*, Jing Liu*, Qingsong Liu*, Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies. Oncotarget 2016, 7(33):53515-53525.
  12. Feiyang Liu, Jinhua Wang, Xingxing Yang, Binhua Li, Hong Wu, Shuang Qi, Cheng Chen, Xiaochuan Liu, Kailin Yu, Wenchao Wang, Zheng Zhao, Aoli Wang, Yongfei Chen, Li Wang, Nathanael S. Gray, Jing Liu*, Xin Zhang*, Qingsong Liu*, Discovery of a Highly Selective STK16 Kinase Inhibitor, ACS Chem. Biol. 2016, 11 (6): 1537–1543.
  13. Feiyang Liu#, Beilei Wang#, Qiang Wang#, Ziping Qi#, Cheng Chen#, Lu-Lu Kong#, Ji-Yun Chen, Xiaochuan Liu, Aoli Wang, Chen Hu, Wenchao Wang, Huiping Wang, Fan Wu, Yanjie Ruan, Shuang Qi, Juan Liu, Fengming Zou, Zhenquan Hu, Wei Wang, Li Wang, Shanchun Zhang, Cai-Hong Yun*, Zhimin Zhai*, Jing Liu*, Qingsong Liu*, Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML), Oncotarget 2016, 7(29):45562-45574.
  14. Hong Wu, Aoli Wang, Ziping Qi, Xixiang Li, Cheng Chen, Kailin Yu, Fengming Zou, Chen Hu, Wenchao Wang, Zheng Zhao, Jiaxin Wu, Juan Liu, Xiaochuan liu, Li Wang, Wei Wang, Shanchun Zhang, Richard M. Stone, Ilene A. Galinsky, James D. Griffin, David Weinstock, Alexandra Christodoulou, Huiping Wang, Yuanyuan Shen, Zhimin Zhai*, Ellen L. Weisberg*, Jing Liu*, Qingsong Liu*, Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML, Leukemia 2016, 30(10): 2112-2116.
  15. Qiang Wang#, Feiyang Liu#, Beilei Wang#, Fengming Zou#, Cheng Chen#, Xiaochuan Liu, Aoli Wang, Shuang Qi, Wenchao Wang, Ziping Qi, Zheng Zhao, Zhenquan Hu, Wei Wang, Li Wang, Shanchun Zhang, Yuexiang Wang, Jing Liu* and Qingsong Liu*, Discovery of N(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3- (trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective Potent, and Orally Available Type II cKIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs), J. Med. Chem. 2016, 59 (8): 3964–3979.
  16. Zhiyuan Li, Xinmiao Ji, Wenchao Wang, Juanjuan Liu, Xiaofei Liang, Hong Wu, Jing Liu, Ulrike S. Eggert, Qingsong Liu, Xin Zhang. Ammonia Induces Autophagy through Dopamine Receptor D3 and MTOR, PLoS One, 2016, 11(4):e0153526.
  17. Xiaochuan Liu#, Aoli Wang#, Xiaofei Liang#, Cheng Chen#, Juanjuan Liu, Zheng Zhao, Hong Wu, Yuanxin Deng, Li Wang, Beilei Wang, Jiaxin Wu, Feiyang Liu, Stacey M. Fernandes, Sophia Adamia, Richard M. Stone, Ilene A. Galinsky, Jennifer R. Brown, James D. Griffin, Shanchun Zhang, Teckpeng Loh, Xin Zhang, Wenchao Wang*, Ellen L. Weisberg*, Jing Liu*, Qingsong Liu*, Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN-015) for B-Cell malignances, Oncotarget 2016, 7(22): 32641-32651.
  18. Aoli Wang#, Hong Wu#, Cheng Chen#, Chen Hu#, Ziping Qi#, Wenchao Wang, Kailin Yu, Xiaochuan Liu, Fengming Zou, Zheng Zhao, Jiaxin Wu, Juan Liu, Feiyang Liu, Li Wang, Richard M. Stone, Ilene A. Galinksy, James D. Griffin, Shanchun Zhang, Ellen L. Weisberg*, Jing Liu*, Qingsong Liu*, Dual Inhibition of AKT/FLT3-ITD by A674563 Overcomes FLT3 Ligand-Induced Drug Resistance in FLT3-ITD positive AML, Oncotarget 2016, 7(20): 29131-29142.
  19. Zhen Zheng, Hongbin Sun, Chen Hu, Gongyu Li, Xiaomei Liu, Peiyao Chen, Yusi Cui, Jing Liu, Junfeng Wang, and Gaolin Liang*, Using “On/Off” 19F NMR/MRI Signals to Sense Tyrosine Kinase/Phosphatase Activity in Vitro and in Cell Lysates, Anal. Chem. 2016, 88(6): 3363-3368.
  20. Xiaofei Liang#, Xiaochuan Liu#, Beilei Wang#, Fengming Zou#, Aoli Wang, Shuang Qi, Cheng Chen, Zheng Zhao,Wenchao Wang, Ziping Qi, Fengchao Lv, Zhenquan Hu, Li Wang, Shanchun Zhang, Qingsong Liu*, and Jing Liu*, Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia, J. Med. Chem. 2016, 59(5): 1984-2004.
  21. Hong Wu#, Chen Hu#, Aoli Wang#, Weisberg Ellen L#, Wang Wenchao, Chen Cheng, Zhao Zheng, Yu Kailin, Liu Juan, Wu Jiaxin, Atsushi Nonami, Wang Li, Wang Beilei, Richard M Stone, S Liu, James D Griffin, Liu Jing* and Liu Qingsong*, Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML, Leukemia 2016, 30(3): 754-757.
  22. Hong Wu#, Chen Hu#, Aoli Wang#, Ellen L. Weisberg#, Yongfei Chen#, Cai-Hong Yun, Wenchao Wang, Yan Liu, Xiaochuan Liu, Bei Tian, Jinhua Wang, Zheng Zhao, Yanke Liang, Binhua Li, Li Wang, Beilei Wang, Cheng Chen, Sara J. Buhrlage, Ziping Qi, Fengming Zou, Atsushi Nonami, Yuyang Li, Stacey M. Fernandes, Sophia Adamia, Richard M. Stone, Ilene A. Galinsky, Xianhuo Wang, Guang Yang, James D. Griffin, Jennifer R. Brown, Michael J. Eck, Jing Liu*, Nathanael S. Gray*, Liu Qingsong*, Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia, Leukemia 2016, 30(1): 173-181.
  23. Xixiang Li#, Aoli Wang#, Kailin Yu#, Ziping Qi#, Cheng Chen, Wenchao Wang, Chen Hu, Hong Wu, Jiaxin Wu, Zheng Zhao, Juan Liu, Fengming Zou, Li Wang, Beilei Wang, Wei Wang, Shanchun Zhang, Jing Liu*, Qingsong Liu*, Discovery of (R)‑1-(3-(4-Amino-3-(4-phenoxyphenyl)‑1Hpyrazolo[3,4‑d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone(CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia, J. Med. Chem. 2015, 58(24): 9625-9638.
  24. Hong Wu#, Aoli Wang#, Wei Zhang#, Beilei Wang#, Cheng Chen#, Wenchao Wang, Chen Hu, Zi Ye, Zheng Zhao, Li Wang, Xixiang Li, Kailin Yu, Juan Liu, Jiaxin Wu, Xiao-E Yan, Peng Zhao, Jinhua Wang, Chu Wang, Ellen L. Weisberg, Nathanael S. Gray, Cai-Hong Yun, Jing Liu*, Liang Chen*, Qingsong Liu*, Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells, Oncotarget 2015, 6(31): 31313-31322.
  25. Hong Wu#, Wenchao Wang#, Feiyang Liu#, Ellen E Weisberg#, Bei Tian, Yongfei Chen, Binhua Li, Aoli Wang, Beilei Wang, Zheng Zhao, Douglas W. McMillin, Chen Hu, Hong Li, Jinhua Wang, Yanke Liang, Sara J. Buhrlage, Junting Liang, Jing Liu, Guang Yang, Jennifer R. Brwon, Steven P. Treon, Constantine S. Mitsiades, James Griffin, Qingsong Liu*, and Nathanael S Gray*, Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma, ACS Chem. Biol. 2014, 9(5): 1086-1091.
  26. Daniel Nedelcu#, Jing Liu#, Yangqing Xu, Cindy Jao and Adrian Salic*, Oxysterol binding to the extracellular domain of Smoothened in Hedgehog signaling, Nat. Chem. Biol. 2013, 9(9): 557-564.
  27. Hanna Tukachinsky, Ryan P. Kuzmickas, Cindy Y. Jao, Jing Liu, and Adrian Salic*, Dispatched and Scube mediate the efficient secretion of the cholesterol-modified Hedgehog ligand, Cell Reports 2012, 2(2): 308-320.
  28. Jing Liu, Yi Hu, David L. Waller, Junfeng Wang and Qingsong Liu*, Natural products as kinase inhibitors, Nat. Prod. Rep. 2012, 29(3): 392-403.
  29. Jing Liu, Yangqing Xu, Dan Stoleru, and Adrian Salic*, Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin, Proc. Natl. Acad. Sci. USA 2012, 109(2): 413-418.
  30. Eunhwa Ko, Jing Liu and Kevin Burgess*, Minimalist and Universal Peptidomimetics, Chem. Soc. Rev. 2011, 40(8): 4411-4421.
  31. Yi Hu, Jing Liu, Junfeng Wang, Qingsong Liu*, The controversial links among calorie restriction, SIRT1, and resveratrol, Free Radic. Biol. Med. 2011, 51(2): 250-256.
  32. Eunhwa Ko, Jing Liu, Lisa M. Perez, Genliang Lu, Amber Schaefer, and Kevin Burgess*, Universal peptidomimetics, J. Am. Chem. Soc. 2011, 133(3): 462-477.
  33. Yujing Bai#, Zhihua Shi#, Yehong Zhuo#, Jing Liu, Andrey Malakhov, Eunhwa Ko, Kevin Burgess, Henry Schaefer, Pedro F. Esteban, Lino Tessarollo* and H. Uri Saragovi*, In glaucoma the up-regulated truncated TrkC.T1 receptor isoform in glia causes increased TNF-α production, leading to retinal ganglion cell death, Invest. Ophthalmol. Vis. Sci. 2010, 51(12): 6639-6651.
  34. Fouad Brahimi#, Jing Liu#, Andrey Malakhov, Shafinaz Chowdhury, Enrico O. Purisima, Ljubica Ivanisevic, Antoine Caron, Kevin Burgess*, H. Uri Saragovi*, A monovalent agonist of TrkA Tyrosine kinase receptors can be converted into a bivalent antagonist, Biochimica et Biophysica Acta-General Subjects 2010, 1800(9): 1018-1026.
  35. Jing Liu, Fouad Brahimi, H. Uri Saragovi*, and Kevin Burgess*, Bivalent diketopiperazine-based tropomysin receptor kinase C (TrkC) antagonists, J. Med. Chem. 2010, 53(13): 5044-5048.